(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Shah Capital frustrated with Novavax's weak COVID-19 vaccine sales Hedge fund increases stake to 8.3%, urges sale to large pharma Novavax's COVID vaccine sales lag behind competitors Nov 13 (Reuters) ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc. (NASDAQ:NVAX) with an Overweight rating and a ...

Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. The Gaithersburg, Maryland-based ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...

The FDA has issued a long-awaited approval of Novavax's COVID-19 vaccine (Nuvaxovid), but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus vaccine -- ...

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

The amendment broadens the partnership between Novavax and Sanofi and adds to the terms of the original agreement that specifies that Novavax is eligible to receive up to $200 million for the first ...

Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...